title: Efficacy and safety of Yinchenwuling powder for hyperlipidemia: a systematic review and Meta-analysis.
abstract: OBJECTIVE
  To assess the clinical effectiveness and adverse effects of Yinchenwuling powder (YCWLP) in the treatment of hyperlipidemia using Meta-analysis.
  
  
  METHODS
  Seven electronic databases were searched for randomized controlled trials designed to evaluate the clinical effectiveness of YCWLP for hyperlipidemia published in any language prior to February 2015. Two reviewers independently identified articles, extracted data, assessed quality, and cross-checked the results. Revman 5.3 was used to analyze the data.
  
  
  RESULTS
  Only five randomized controlled trials with poor methodology were included in the analysis. The five trials compared YCWLP with conventional lipid-lowering drugs. Meta-analysis indicated that YCWLP was more effective at the levels of total cholesterol and triglycerides, while increasing the level of high-density lipoprotein cholesterol without serious adverse effects. However, it was not more effective than lipid-lowering drugs in reducing low-density lipoprotein cholesterol and improving hemorheology.
  
  
  CONCLUSIONS
  YCWLP appeared to improve lipid levels. However, given the high risk of bias among the trials, we could not conclude that YCWLP was beneficial to patients with hyperlipidemia. More rigorous trials are required to provide stronger evidence for the conclusion.
authors.forename: Haiqiang
authors.initials: H
authors.lastname: Yao
authors.forename: Zengliang
authors.initials: Z
authors.lastname: Zhang
authors.forename: Ji
authors.initials: J
authors.lastname: Wang
authors.forename: Jiacheng
authors.initials: J
authors.lastname: Zuo
authors.forename: Yu
authors.initials: Y
authors.lastname: Chen
authors.forename: Libing
authors.initials: L
authors.lastname: Zhu
authors.forename: Xiaoke
authors.initials: X
authors.lastname: Li
authors.forename: Zheng
authors.initials: Z
authors.lastname: Yang
authors.forename: Zisong
authors.initials: Z
authors.lastname: Wang
authors.forename: Ranran
authors.initials: R
authors.lastname: Sun
authors.forename: Xuanxuan
authors.initials: X
authors.lastname: Xu
authors.forename: Changming
authors.initials: C
authors.lastname: Li
authors.forename: Yanling
authors.initials: Y
authors.lastname: Wu
authors.forename: Lingru
authors.initials: L
authors.lastname: Li
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
mesh_terms: D002784:Cholesterol / Q000378:metabolism; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D014280:Triglycerides / Q000378:metabolism
chemical_list: D004365:Drugs, Chinese Herbal; D000960:Hypolipidemic Agents; D014280:Triglycerides; D002784:Cholesterol